Novartis
NVS
$119.45
Share price
-1.09%
Change (1 day)
12.67%
Change (1 year)
Categories
Novartis AG is a biotechnology and pharmaceutical company based in Basel, Switzerland. Novartis was formed in 1996 from a merger of the two Basel pharmaceutical and chemical companies Ciba-Geigy AG and Sandoz AG. Novartis is one of the largest pharmaceutical companies in the world with sales of USD 47.4 billion in 2019.
Market capitalization of Novartis (NVS)
Market cap: $235.92 Billion USD
As of June 2025 Novartis has a market cap of $235.92 Billion USD. This makes Novartis the world's 53th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Novartis from 1998 to 2025
End of year Market Cap
| Year | Marketcap | Change |
|---|---|---|
| 2025 | $235.92 B | 19.94% |
| 2024 | $196.70 B | -5.22% |
| 2023 | $207.53 B | 6.35% |
| 2022 | $195.13 B | -0.68% |
| 2021 | $196.46 B | -9.78% |
| 2020 | $217.77 B | 1.37% |
| 2019 | $214.83 B | 8.9% |
| 2018 | $197.28 B | 0.05% |
| 2017 | $197.18 B | 13.99% |
| 2016 | $172.98 B | -17.02% |
| 2015 | $208.46 B | -6.94% |
| 2014 | $224.01 B | 15.09% |
| 2013 | $194.64 B | 27.77% |
| 2012 | $152.33 B | 10.31% |
| 2011 | $138.09 B | 2.61% |
| 2010 | $134.58 B | 7.64% |
| 2009 | $125.03 B | 10.95% |
| 2008 | $112.69 B | -8.36% |
| 2007 | $122.98 B | -8.82% |
| 2006 | $134.88 B | 10.03% |
| 2005 | $122.58 B | -0.05% |
| 2004 | $122.65 B | 8.31% |
| 2003 | $113.24 B | 24.58% |
| 2002 | $90.90 B | -2.26% |
| 2001 | $93.00 B | -20.27% |
| 2000 | $116.64 B | 21.34% |
| 1999 | $96.13 B | -28.38% |
| 1998 | $134.22 B |
End of Day market cap according to different sources
On Jun 13th, 2025 the market cap of Novartis was reported to be:
$236.00 Billion USD
$235.92 Billion USD
Market capitalization for similar companies or competitors
| Name | Marketcap | Market cap differencediff. | Country |
|---|---|---|---|
 Merck MRK | $205.17 B | -13.03% | 🇺🇸 USA |
 Pfizer PFE | $139.51 B | -40.86% | 🇺🇸 USA |
 Johnson & Johnson JNJ | $377.99 B | 60.22% | 🇺🇸 USA |
 Sanofi SNY | $120.94 B | -48.73% | 🇫🇷 France |
 GlaxoSmithKline GSK | $82.77 B | -64.91% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | $19.56 B | -91.71% | 🇮🇱 Israel |
 Bristol-Myers Squibb BMY | $101.24 B | -57.09% | 🇺🇸 USA |
 Abbott Laboratories ABT | $235.95 B | 0.01% | 🇺🇸 USA |
 AstraZeneca AZN | $230.73 B | -2.20% | 🇬🇧 UK |